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Tuesday, March 8, 2011 413arelease dysfunction. Cardiac electrical dysfunction in CPVT is remarkably sim-
ilar to that elicited by digitalis toxicity and a related glycoside, ouabain, has
been identified as an endogenous Ca2þ-mobilising ‘hormone’. Circulating
levels of adrenally-derived ouabain are reportedly elevated in heart failure
and post-exercise. Here we investigated whether physiologic levels of ouabain
could provoke mutant RyR2 channel dysfunction. In single HL-1 cardiomyo-
cytes, ouabain (EC50 = 14.3nM) perturbed Ca2þ homeostasis in a manner
strikingly similar to that determined in cells expressing CPVT-linked
R4497C mutation. Moreover, dose-dependent ouabain-evoked Ca2þ dysfunc-
tion resulted in a left-shifted caffeine activation profile typical of mutant RyR2
channels. LC/MS/MS analysis determined equivalent levels of ouabain in se-
rum obtained from CPVT- and normal subjects (500-800pM) and exercise
stress-testing did not acutely elevate ouabain levels in either cohort. In cells ex-
pressing the R4497C mutation, which exhibited basal Ca2þ dysfunction, addi-
tion of ouabain at physiologic (1nM) and supra-physiologic (10-100nM)
concentrations did not further exacerbate cellular Ca2þ abnormalities. In con-
trast, the addition of serum obtained from exercised normal and CPVT subjects
(100ug protein equivalents; ~2pM ouabain) evoked hallmark mutation-linked
RyR2 dysfunction that was not completely abolished by b-blockade. These
findings confirm that non-catecholaminergic factors contribute to RyR2 mutant
dysfunction, but preclude the possibility that endogenous ouabain is a physio-
logically relevant trigger of CPVT. However, the hypothesis that endogenous
ouabain may induce underlying changes in excitation-contraction coupling
that increase the propensity for mutation-linked RyR2 dysfunction is being
investigated.
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The Effect of Adrenergic Stimulation on the Calcium Release Channel
Jiao Li, Nicole A. Beard, Angela F. Dulhunty, Dirk F. vanHelden,
Derek R. Laver.
Adrenergic stimulation of the heart involves phosphorylation of many intracel-
lular Ca2þ handling proteins including the ryanodine receptor Ca2þ release
channels in the SR (RyRs). It is known that RyRs can be phosphorylated at
three serine residues at 2808, 2814 and 2030 and that phosphorylation of
RyRs via PKA causes an increase in RyR activity in situ. However, little is
known about how phosphorylation of RyRs in the cell alters their regulation
by intracellular Ca2þ and Mg2þ.
RyRs were isolated from rat hearts, which had been rapidly removed, perfused
with Krebs buffer in a Langendorff apparatus. Some hearts were perfused with
1 mM isoproterenol for sufficient time to increase heart rate by>60% for 1 min
and others without isoproterenol for 5 mins. Hearts were snap frozen in liquid
N2 to capture their state of phosphorylation, thus allowing RyRs to be phos-
phorylated by the physiological signalling processes. RyRs were incorporated
into artificial planar lipid bilayers and their activity was measured using single
channel recording.
The activity of RyRs from isoproterenol stimulated hearts (ISO RyRs, n=25)
was 3-fold higher than control RyRs (n=24) at diastolic [Ca2þ] (100 nM) but
was not significantly different at systolic [Ca2þ] (>1 mM). At diastolic
[Ca2þ], addition of Protein Phosphatase1 (PP1, 5 mins) reduced the activity
of ISO RyRs by 98 5 2.6% (n=4) and control RyRs by 70 5 20 % (n=4)
but this treatment had no effect at systolic [Ca2þ]. ISO RyRs displayed
a 100-fold channel-to-channel variation in activity which was larger than,
and encompassed the range of activity seen either for control RyRs or PP1
treated RyRs. The results indicate that adrenergic stimulation increases RyR2
activity during diastole but not during systole.
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The Functional Impact of Cis Acting Ryanodine Receptor Type 1
Mutations in a Child with a Fatal Spontaneous MH Event
Linda Groom, Sheila Muldoon, Munkhuu Bayarsaikhan, Saiid Bina,
Hee-Suk Lee, Barbara W. Brandom, Nyamkhishig Sambuughin,
Robert T. Dirksen.
Mutations in the RYR1 gene result in MH, a pharmacogenetic disorder of
skeletal muscle typically triggered by administration of anesthetics. How-
ever, cases of sudden death during exertion, heat challenge, and febrile ill-
ness in the absence of triggering drugs have been reported in individuals
with RYR1 gene variants. We describe the clinical history and genetic anal-
ysis of a child that suffered a fatal, non-anesthetic MH episode associated
with febrile illness who was heterozygous for two novel RYR1 variants
where one variant, R3983C, occurred de-novo and another, D4505H, was in-
herited. Effects of the two variants on RYR1 sensitivity to activation by caf-
feine were assessed following expression in RYR1-null myotubes. The
single (R3983C and D4505H) and double (R3983C-D4505H) variants
were engineered into a full-length rabbit RYR1 cDNA and introduced
into RyR1-null myotubes via nuclear microinjection. Effects of the differentheterotypic expression conditions (WTþR3983C, WTþD4505H,
R3983CþD4505H, and WTþR3983C-D4505H) on RYR1 activation by caf-
feine were determined in indo-1-loaded myotubes. Compared to WT RYR1
alone (EC50 = 1.5 mM), the caffeine sensitivity of RYR1 Ca
2þ release was
only modestly increased following co-expression of either R3983C (EC50 =
1.3 mM) or D4505H (EC50 = 0.9 mM). Remarkably, co-expression of WT
RYR1 with the double mutant in cis (R3983C-D4505H) produced a much
stronger sensitization of caffeine-induced release (EC50 = 0.3) than that ob-
served following co-expression of the two variants on separate subunits
(EC50 = 0.9). Thus, the R3893C mutation potentiates D4505H-mediated sen-
sitization of caffeine-induced RYR1 Ca2þ release when these mutations are
in cis or present on the same subunit, but not when present on separate sub-
units. These results indicate that allelic segregation can be a critical, and
heretofore unappreciated, pathogenic factor in compound heterozygous
MH individuals.
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GSTM2 C Terminus Reduces Calcium Release Through RyR2 in Sponta-
neously Contracting and Field Stimulated Ventricular Cardiomyocytes
Ruwani P. Hewawasam, Marco G. Casarotto, Philip G. Board,
Angela F. Dulhunty.
The ryanodine receptor (RyR) is an ion channel that releases Ca2þ from the sar-
coplasmic reticulum and is essential for excitation-contraction coupling and
contraction in striated muscle. Previously we reported that the human muscle
specific glutathione transferase (GSTM2-2) is an inhibitor of cardiac muscle
RyR2 and a weak activator of skeletal muscle RyR1. Single channel experi-
ments and Ca2þ release assays using the C-terminal half of GSTM2-2
(GSTM2C) and the mutants, F157A and Y160A in the C terminal domain con-
firmed the importance of helix 6 in the C-terminal (non-enzymic) fold for in-
hibition of RyR2. The objective of this study was to determine the effect of
GSTM2C on the cardiac myocyte function.
Primary cardiomyocytes were cultured from neonatal rats. Spontaneous or
field- stimulated (1Hz with 3V, 2ms pulses) contraction was recorded in control
and 15mMGSTM2C-treated cells using a JVC video camera KY/F550 attached
to Nikon TE2000-U microscope. Images were analysed using Image Pro plus
6.2 software and percentage cell shortening measured.
Preliminary results showed that spontaneous contraction frequency fell from
42.5/min in the control group to 6.9 /min after GSTM2C treatment
(P<0.001). The number of spontaneously beating cells fell from 6.6% in the
control group to 1.9% after treatment (P<0.001). To determine whether the re-
duced contractions were due to the GSTM2 C terminus affecting action poten-
tials or contraction, shortening was measured. Shortening in spontaneous
contraction fell from 7.551.0% in control to 2.950.6% after GSTM2C treat-
ment (P<0.001). Shortening after field stimulation also fell, from 7.350.8%
before to 4.150.6% after, GSTM2C-treatment (P<0.01). These results are
consistent with GSTM2 C reducing contraction in ventricular cardiomyocytes
by reducing Ca2þ release through RyR2.
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In Situ Measurement of RyR2-Calmodulin Binding in Permeabilized
Cardiomyocytes
Yi Yang, Asima Chakraborty, Tao Guo, Razvan L. Cornea,
Gerhard Meissner, Donald M. Bers.
Calmodulin (CaM) is a Ca-sensing protein and important regulator to RyR2.
Defective CaM association with and regulation of RyR2 has been implicated
in cardiac hypertrophy, heart failure and Catecholaminergic Polymorphic Ven-
tricular Tachycardia. However, direct measurement of the RyR-CaM binding
properties in myocytes is lacking despite its potential clinical importance.
This is most likely due to the interference from CaM’s multiple binding targets,
such as L-type Ca channel, Calcineurin, and CaMKII. Fluorescence Resonance
Energy Transfer (FRET) was used to measure the RyR2-specific bound CaM in
permeabilized rat and mouse cardiomycytes. FKBP12.6 and CaM bind to RyR2
in close physical proximity so that strong FRET can be detected between fluo-
rescently labeled FKBP12.6 (F-FKBP12.6) and F-CaM. To confirm the speci-
ficity of CaM binding to RyR2 and measure the percentage of CaM visible at
the Z-line is RyR-bound under physiological conditions, we used mutant RyR2
knock-in mice expressing a triple mutation in the RyR2 (RyR2ADA). The mu-
tation prevents CaM binding to RyR2 but should not alter binding of CaM to
other targets. Our data showed that 1) the apparent Kd of CaM to RyR in rat
cardiac myocytes (at 100 nM [Ca]) was 18.25 2nM (n=XX); 2) heterozygous
RyR2ADA/þ mutation decreased the maximal binding sites (on RyR2) by 50%
without appreciably altering affinity in mouse myocytes (Kd =16.95XX nM in
RyR2ADA/þ and 13.45XX nM, inWTmice, p< 0.05); 3) The total CaM bind-
ing visible at the Z-line was reduced by 45%, implying that ~90% of Z-line
414a Tuesday, March 8, 2011CaM is RyR2 bound. These results are the first quantitative in situ RyR2-CaM
binding measurements.
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A Region Involved in Isoform-Specific Regulation of Skeletal Muscle Rya-
nodine Receptor by Calmodulin
Naohiro Yamaguchi, Le Xu, Gerhard Meissner.
Calmodulin (CaM) regulates both skeletal (RyR1) and cardiac (RyR2) muscle
ryanodine receptor calcium channels by binding to a single highly conserved
CaM binding domain (RyR1 amino acid (aa) 3614-3643; RyR2 aa 3581-
3610). CaM inhibits both isoforms at an elevated Ca2þ concentration (micro-
mollar), whereas at cellular resting Ca2þ concentration CaM has opposite
effects on two isoforms (activation of RyR1 and inhibition of RyR2). This im-
plies another region of RyR is involved in isoform-specific CaM regulation at
submicromollar Ca2þ concentration. To identify the regions we constructed
and analyzed a series of RyR1/RyR2 chimera. RyR1/RyR2 chimera carrying
RyR1 aa 1-3725 is inhibited by CaM at 0.4 mMCa2þ (RyR2-type), whereas chi-
mera carrying RyR1 aa 1-4301 is activated (RyR1-type). The results suggest
that RyR1 aa 3726-4301 contains a region that is responsible for CaM activa-
tion. The region overlaps with a domain resembling the sequence of CaM
(CaM-like domain). Replacement of RyR1 3726-4301 with the corresponding
RyR2 sequence confers CaM inhibition at [Ca2þ]<1 mM (RyR2 type). Further-
more, substitution of 5 non-conserved amino acids in RyR1 CaM-like domain
with those of RyR2 (M4122T, I4123L, N4124D, F4125Y, N4130K) is suffi-
cient for RyR2-type CaM inhibition. However, the reverse chimera and mutant
RyR2 were not activated but inhibited by CaM. Taken together, the results sug-
gest that 5 non-conserved amino acids of RyR1 are crucial for RyR1-specific
CaM activation at submicromollar Ca2þ concentration. On the other hand,
CaM inhibition of RyR2 is likely controlled by a different region. Supported
by NIH (AR018687 and HL073051), NSF (EPS-0903795) and AHA
(10SDG3500001).
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Effect of Human RyR2 CPVT Mutations on Interaction with Calmodulin
Peter Wilson, Michail Nomikos, Matthias Bochtler, F. Anthony Lai.
The ryanodine receptor (RyR) is a member of a family of intracellular calcium
release channels that regulate calcium efflux from intracellular stores. The
RyR2 isoform is most abundant in the heart and plays a key role in cardiac mus-
cle excitation-contraction coupling. Clusters of mutations associated with the
inherited arrhythmogenic disorder, catecholaminergic polymorphic ventricular
tachycardia (CPVT), have been found in specific regions throughout RyR2,
a large protein of ~5000 amino acids. Many of these CPVT mutations (total
>100) are thought to occur in significant functional domains and result in
the dysregulation of RyR channel function.
One such region of RyR2 is believed to comprise a calmodulin (CaM) interac-
tion site and two EF hand motifs. The calcium-sensitive binding of CaM has
been shown to regulate the opening of RyR. Hence, examining the RyR2 inter-
action with CaM and the potential effects of CPVT mutations on this binding
may help reveal mutation-dependent mechanisms of channel dysfunction.
We have prepared bacterial expression plasmid constructs containing the wild-
type human RyR2 CaM-interacting domain and introduced a series of CPVT
mutations that have previously been identified to occur within this region. Ex-
pression and purification of the corresponding recombinant fusion proteins has
enabled calcium-dependent binding of CaM to be determined with all these
constructs. Examining the distinct functional role of calcium concentration
on CaM binding kinetics and further comparative structural analyses of the
wild-type and mutant RyR2 domains may help reveal the specific effect(s)
that CaM-mediated regulation may have in mediating CPVT-linked
arrhythmogenesis.
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Direct Detection of Domain Peptide Binding to the Cardiac Ryanodine
Receptor (RYR2) using FRET
Florentin R. Nitu, Razvan L. Cornea, David D. Thomas, Bradley R. Fruen.
The RyR2 Ca release channel is activated by the synthetic domain peptide
DPc10, which corresponds to a 36-residue sequence within the channel’s cen-
tral mutation hot-spot region. DPc10 activation is hypothesized to result from
the destabilization of a critical intramolecular interaction between the N-termi-
nal and central hot-spot regions of the full-length RyR2, and to thereby mimic
the effects of arrhythmogenic mutations on this putative intramolecular interac-
tion controlling channel activation. However, the site of DPc10 binding within
the RyR2 3D structure is uncertain, and factors that may modulate binding are
undefined. To directly monitor and map DPc10 binding to the RyR2, we at-
tached a FRET acceptor at DPc10’s N-terminus. A FRET donor was targeted
to the RyR2 cytoplasmic assembly via a fluorescent-labeled FKBP12.6. Addi-
tion of the acceptor-labeled DPc10 (30 mM) resulted in a marked decrease influorescence of the RyR2-bound FKBP12.6. Fluorescence was partially re-
stored upon FKBP12.6 dissociation from the RyR2, indicating that a major
fraction of the total fluorescence decrease was attributable to FRET between
FKBP12.6 and DPc10 when bound to the channel. The DPc10 dependence
of FRET was similar to the DPc10 dependence of RyR2 activation observed
previously in bilayer and ryanodine binding studies (EC50 ~25 mM), consistent
with the likelihood that FRET reflected DPc10 binding at its regulatory site on
the RyR2. FRET decreased as a function of increasing Ca (30 nM to 300 mM),
suggesting that Ca activation of the RyR2 altered either the affinity of DPc10
binding or its proximity to the FKBP12.6 subunit. We conclude that DPc10
binds to a site on the RyR2 within 10 nm of FKBP12.6. Regulatory interactions
and structural changes at this site can be monitored using FRET.
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b Strand Switching: A Novel Structural Rescue Mechanism in a Dexon3
Cardiac Ryanodine Receptor Mutant
Paolo A. Lobo, Lynn Kimlicka, Ching-Chieh Tung, Filip Van Petegem.
The contraction of cardiac muscle requires release of Ca2þ from the sarcoplas-
mic reticulum through the cardiac ryanodine receptor (RyR2). Several muta-
tions in RyR2 are linked to inherited disorders, including triggered cardiac
arrhythmias such as catecholaminergic polymorphic ventricular tachycardia
(CPVT) that may lead to sudden cardiac death. A severe form of CPVT is
caused by removal of an entire third exon (Dexon3) of RyR2. The 35 deleted
residues form secondary structure elements which are crucial in folding of
the N-terminal domain, raising the question of why the deletion is neither lethal
nor confers a loss-of-function phenotype. A 2.3A˚ crystal structure shows that
the removal results in a structural rescue: an otherwise flexible loop compen-
sates for the loss by inserting itself into the b trefoil domain and increases
the thermal stability. The other b strands in the domain show increased mobility
to accommodate a sequence that bears no similarity to the deleted exon. The
exon3 deletion is not tolerated in the corresponding RyR1 domain. The rescue
shows a novel mechanism by which RyR2 channels can adjust their Ca2þ re-
lease properties through altering the structure of an individual domain.
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Crystallographic Investigation of Several Malignant Hyperthermia and
CPVT Mutations in Ryanodine Receptors
Lynn Kimlicka, Filip Van Petegem.
Mutations in the Ryanodine Receptor (RYR) are known to underlie many ge-
netic diseases. In particular, the skeletal muscle isoform (RyR1) is involved in
malignant hyperthermia (MH) and central core disease (CCD), whereas muta-
tions in the cardiac isoform (RyR2) are known to cause catecholaminergic
polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventric-
ular dysplasia (ARVD). Despite an extensive analysis of disease mutations on
the functional level, very little is known about the structural changes induced
by the mutations. Here we analyze the structures and stability of over 10 differ-
ent disease mutants. We present crystal structures of mutant versions of the
RyR1 N-terminal disease hot spot, encoding three domains, and of the RyR2
N-terminal domain, all solved between 2.0 and 3.0 Angstrom, and compare
them to the wild type structures. The observed effects on structure and stability
differ substantially among the mutants. Whereas some cause a major destabili-
zation of the overall fold, others mainly cause relative domain-domain move-
ments or confer large conformational changes within individual domains. We
discuss the likely implications of the disease mutations on the overall structure
and gating properties of the intact RyR.
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AModel-Based Description and Burst Analysis of Purified HumanCardiac
Ryanodine Receptor (hRyR2) Gating Kinetics Under Minimal Conditions
Saptarshi Mukherjee, Nia Lowri Thomas, Chloe E. Maxwell,
Alan J. Williams.
Rhythmic contraction of cardiacmyocytes is maintained by precisely controlled
Ca2þ efflux from intracellular stores mediated by the cardiac ryanodine receptor
(RyR2). Mutations in RyR2 can cause channel instability leading to perturbed
Ca2þ release that can trigger arrhythmias. RyR2-dependent ventricular tachyar-
rhythmia is an important cause of sudden cardiac death, the mechanistic basis of
which remains unclear. Most investigations of RyR2 single channel function
have focussed on the secondary effects ofmutations on channel function through
modulation by regulatory proteins and cellular processes without emphasis on
mutation-dependent effects on the gating behaviour of the channel itself. Here
we describe the gating kinetics of wild-type hRyR2 when activated by its phys-
iological trigger, cytosolic Ca2þ and isolated from the possible modulatory ef-
fects of regulatory factors external to the channel. Single channel experiments
were performed using recombinant, purified hRyR2 under reducing conditions
where the luminal Ca2þ was buffered at 50 nM while the cytosolic Ca2þ was
stringently controlled using EGTA, HEDTA and NTA to achieve an activating
